Skip to Content

Regeneron Pharmaceuticals, Inc.

Securities Class Action

  • Date:
  • 4/17/2024
  • Company Name:
  • Regeneron Pharmaceuticals, Inc.
  • Stock Symbol:
  • REGN
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of Regeneron stockholders. Our investigation concerns whether Regeneron has violated the federal securities laws and/or engaged in other unlawful business practices.

Regeneron is the subject of a DOJ lawsuit filed on April 10, 2024. The lawsuit accuses Regeneron of failing to report millions of dollars in discounts given to drug distributors. These discounts were provided as reimbursements for credit card processing fees. As a result, the DOJ alleges that the average selling price of Regeneron's Eylea drug was inflated above the amount allowed by Medicare.

If you purchased or otherwise acquired Regeneron shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Regeneron Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: